Evidence map›Paper›PMID 34162914›Full record

ArticleScientific reports2021

CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe.

R Paul Duffin, Michael Delbuono, Kylie Nishioka, Paul Shabram, Amish A Patel

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

R Paul DuffinEmergent BioSolutions, Inc., Gaithersburg, MD, 20879, USA. duffinp@ebsi.com.
Michael DelbuonoEmergent BioSolutions, Inc., Gaithersburg, MD, 20879, USA.
Kylie NishiokaEmergent BioSolutions, Inc., Gaithersburg, MD, 20879, USA.
Paul ShabramEmergent BioSolutions, Inc., Gaithersburg, MD, 20879, USA.
Amish A PatelEmergent BioSolutions, Inc., Gaithersburg, MD, 20879, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CVD 103-HgR live, attenuated oral cholera vaccine strain is indicated for single dose immunization against Vibrio cholerae, the causative agent for cholera. The vaccine packets containing buffer powder and lyophilized CVD 103-HgR are reconstituted in water and consumed. Studies were performed to explore the viability of CVD 103-HgR in drinking waters from common sources. CVD 103-HgR vaccine was reconstituted in bottled and tap waters from the United States and Europe, and viability was measured via colony forming units assay. Chemical analysis of select water samples was used to identify chemicals that have a negative effect on CVD 103-HgR viability. CVD 103-HgR titers were stable in all bottled waters tested, including purified bottled water, bottled spring water, and sparkling waters. However, tap water from certain cities in the US and Europe affected viability and are not compatible with vaccine. Water chemistry revealed that these tap waters contained copper, likely leached from copper plumbing. These studies give high confidence in the stability of CVD 103-HgR reconstituted in a variety of bottled waters. Waters containing copper, including tap water, should not be used to reconstitute CVD 103-HgR strain oral vaccine due to the common use of copper plumbing.

Indexed as

Cholera VaccinesBacterial LoadChlorineCopperDrinking WaterEuropeFluoridesHydrocarbons, HalogenatedSanitary EngineeringTrihalomethanesUnited StatesVaccines, AttenuatedVibrio choleraeWater PurificationbromochloromethanebromoformChlorinechlorodibromomethanecholera vaccine CVD 103-HgRCholera VaccinesCopperDrinking WaterFluoridesHydrocarbons, HalogenatedTrihalomethanesVaccines, Attenuated

Identifiers

PMID34162914
PMCPMC8222213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.